171 related articles for article (PubMed ID: 10790349)
1. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
Jollis JG; Landolfo CK; Kisslo J; Constantine GD; Davis KD; Ryan T
Circulation; 2000 May; 101(17):2071-7. PubMed ID: 10790349
[TBL] [Abstract][Full Text] [Related]
2. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
[TBL] [Abstract][Full Text] [Related]
3. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
[TBL] [Abstract][Full Text] [Related]
5. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
6. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
[TBL] [Abstract][Full Text] [Related]
7. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
[TBL] [Abstract][Full Text] [Related]
8. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
9. Valvular heart disease associated with fenfluramine-phentermine.
Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
[TBL] [Abstract][Full Text] [Related]
10. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
11. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
Sachdev M; Miller WC; Ryan T; Jollis JG
Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432
[TBL] [Abstract][Full Text] [Related]
12. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.
Lepor NE; Gross SB; Daley WL; Samuels BA; Rizzo MJ; Luko SP; Hickey A; Buchbinder NA; Naqvi TZ
Am J Cardiol; 2000 Jul; 86(1):107-10. PubMed ID: 10867106
[No Abstract] [Full Text] [Related]
13. Regression and progression of valvulopathy associated with fenfluramine and phentermine.
Dahl CF; Allen MR
Ann Intern Med; 2002 Mar; 136(6):489. PubMed ID: 11900508
[No Abstract] [Full Text] [Related]
14. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
[TBL] [Abstract][Full Text] [Related]
15. Valvular heart disease associated with fenfluramine-phentermine.
Rasmussen S; Corya BC; Glassman RD
N Engl J Med; 1997 Dec; 337(24):1773; author reply 1775. PubMed ID: 9411248
[No Abstract] [Full Text] [Related]
16. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB
Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711
[TBL] [Abstract][Full Text] [Related]
17. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.
Volmar KE; Hutchins GM
Arch Pathol Lab Med; 2001 Dec; 125(12):1555-61. PubMed ID: 11735689
[TBL] [Abstract][Full Text] [Related]
18. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
Teramae CY; Connolly HM; Grogan M; Miller FA
Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073
[TBL] [Abstract][Full Text] [Related]
19. The longitudinal effects of fenfluramine-phentermine use.
Fleming RM; Boyd LB
Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.
Burger AJ; Sherman HB; Charlamb MJ; Kim J; Asinas LA; Flickner SR; Blackburn GL
J Am Coll Cardiol; 1999 Oct; 34(4):1153-8. PubMed ID: 10520805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
